Immuneering公布Atebimetinib联合化疗一线治疗转移性胰腺癌患者的中位总生存期达17.3个月

美股速递
May 22

Immuneering公司近日公布了一项临床数据,显示在接受Atebimetinib联合化疗作为一线治疗的转移性胰腺癌患者中,中位总生存期达到了17.3个月。这一结果对于晚期胰腺癌的治疗领域具有重要意义。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10